Sodium butyrate with UCN-01 has marked antitumour activity against cervical cancer cells.
Decrion-Barthod
Anne-Zélie
AZ
Franche-Comte University, EA 3181, IFR 133, University Hospital, Besançon, France.
Bosset
Matthieu
M
Plissonnier
Marie-Laure
ML
Marchini
Antonio
A
Nicolier
Magalie
M
Launay
Sophie
S
Prétet
Jean-Luc
JL
Rommelaere
Jean
J
Mougin
Christiane
C
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002087:Butyrates / Q000008:administration & dosage / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D005260:Female; D006367:HeLa Cells; D052162:Human papillomavirus 16 / Q000302:isolation & purification; D052161:Human papillomavirus 18 / Q000302:isolation & purification; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D030361:Papillomavirus Infections / Q000473:pathology / Q000821:virology; D019311:Staurosporine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D023041:Xenograft Model Antitumor Assays
D002087:Butyrates; C054852:7-hydroxystaurosporine; D019311:Staurosporine